Arakoda Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888558 60 DEGREES PHARMS Regimens of tafenoquine for prevention of malaria in malaria-naive subjects
Dec, 2035

(11 years from now)

US10342791 60 DEGREES PHARMS Regimens of tafenoquine for prevention of malaria in malaria-naive subjects
Dec, 2035

(11 years from now)

US11744828 60 DEGREES PHARMS Regimens of tafenoquine for prevention of malaria in malaria-naïve subjects
Dec, 2035

(11 years from now)



Arakoda is a drug owned by 60 Degrees Pharmaceuticals Inc. It is used for preventing malaria in adults through a three-phase dosing regimen. Arakoda uses Tafenoquine Succinate as an active ingredient. Arakoda was launched by 60 Degrees Pharms in 2018. It is is available in tablet form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 02, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 08, 2021
New Chemical Entity Exclusivity(NCE) Jul 20, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using TAFENOQUINE SUCCINATE ingredient

NCE-1 date: 20 July, 2022

Market Authorisation Date: 08 August, 2018

Treatment: For the oral prevention/prophylaxis of malaria in adults, comprising a three-phase dosing regimen consisting of a loading/initial dose, a maintenance/exposure dose, and a terminal/post-exposure dose

Dosage: TABLET

More Information on Dosage

ARAKODA family patents

Family Patents